Vanesa Garrido-Rodríguez

Vanesa Garrido-Rodríguez

Auto-generated profile, based on publicly available information

Vanesa Garrido-Rodríguez

Servicio de Inmunología, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
VGVanesa Garrido-Rodríguez
Vanesa Garrido-Rodríguez
ÁBÁngel Bulnes-Ramos
Ángel Bulnes-Ramos
IOIsrael Olivas-Martínez
Israel Olivas-Martínez
MPMaría del Mar Pozo-Balado
María del Mar Pozo-Balado
AÁAna Isabel Álvarez-Ríos
Ana Isabel Álvarez-Ríos
YPYolanda María Pacheco
Yolanda María Pacheco
Persistence of a low CD4/CD8 ratio is associated with an increased morbimortality in people living with HIV (PLWH) under effective antiretroviral therapy. We aimed to explore the immunological significance of a persistently low CD4/CD8 ratio, even despite normal CD4 levels, and assess whether these features vary from those associated to a low nadir-CD4, another well-established predictor of disease progression. CD4-recovered PLWH were classified by CD4/CD8 ratio after three-years of ART (viral suppression, CD4≥500; R < 0.8, n = 24 and R > 1.2, n = 28). sj/β-TRECs ratio and inflammatory-related markers were quantified. PBMCs were immunophenotyped by CyTOF and functionally characterized by ELISPOT. Subjects were also reclassified depending on nadir-CD4 (N ≤ 350/N > 350). R < 0.8 showed a differential inflammatory profile compared to R > 1.2 (increased β2-microglobulin, D-dimers and IP-10 before ART). R < 0.8 presented lower baseline thymic function, being inversely correlated with post-ART inflammation. R < 0.8 at follow-up showed most alterations in CD8 subsets (increasing frequency and exhibiting a senescent phenotype [e.g., CD57+, CD95+]) and enhanced T-cell IFNγ/IL-2 secretion. However, comparing N ≤ 350 to N > 350, the main features were altered functional markers in CD4 T-cells, despite no differences in maturational subsets, together with a restricted T-cell cytokine secretion pattern. Persistence of low CD4/CD8 ratio in successfully-treated PLWH, with normal CD4 counts, is associated with baseline inflammation and low thymic function, and it features post-therapy alterations specific to CD8 T-cells. Differently, subjects recovered from low nadir-CD4 in this setting feature post-therapy alterations on CD4 T-cells. Hence, different mechanisms of disease progression could underlie these biomarkers, potentially requiring different clinical approaches.

24 April 2026 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
Irene Díaz-AlberolaIrene Díaz-Alberola
Irene Díaz-Alberola
DSDaniel Enrique Di Zeo Sánchez
Daniel Enrique Di Zeo Sánchez
VGVanesa Garrido-Rodríguez
Vanesa Garrido-Rodríguez
CLCarlos López-Gómez
Carlos López-Gómez
CRCristina Rodríguez-Díaz
Cristina Rodríguez-Díaz
EGEduardo Garcia-Fuentes
Eduardo Garcia-Fuentes
Drug-induced liver injury (DILI) is an adverse hepatic reaction with a complex etiopathogenesis, involving direct cellular damage by the drug, immune-mediated mechanisms, and host and environmental factors. The gut microbiota has recently been recognized as a key player in human physiopathology. In DILI, animal models and patients have shown significant alterations in gut microbiota composition. Evidence indicates that patients with DILI often present intestinal barrier dysfunction, characterized by increased permeability and the translocation of pathogen-associated molecular patterns (PAMPs) to the liver. This process may contribute to the onset or aggravation of liver injury by triggering harmful immune responses. Furthermore, dysbiosis can alter bacterial metabolite production, thereby affecting intestinal and hepatic homeostasis. The gut microbiota can also modify the efficacy and toxicity of drugs on an individual level, thereby increasing the risk of DILI. This review provides an overview of the current evidence on the mechanisms by which the gut microbiota contributes to inflammation, immune recruitment, and exacerbation of liver damage in DILI. A more in-depth understanding of how the gut microbiota alters intestinal and hepatic homeostasis is essential for advancing our knowledge of DILI pathogenesis, integrating novel biomarkers into clinical practice, and developing microbiota-based interventions.